Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

NCT00326885 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Ascites

Interventions

DRUG: catumaxomab

Sponsor

Neovii Biotech

Collaborators

[object Object]